SOBI:STO
Biovitrum
428,40 SEK
arrow_upward
+1,42%(+6,00) 1 D
9. okt., 17:29:43 GMT+2 · SEK
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for SOBI …
Åpne
427,60 SEK
Høy
431,60 SEK
Lav
426,60 SEK
Markedsverdi
153,21 mrd.
Snittvolum
268,70k
Volum
179,02k
P/E-forhold
114,42
52 u høy
487,00 SEK
52 u lav
293,60 SEK
EPS
3,74 SEK
Utestående aksjer
357,64 mill.
Antall ansatte
2k
Åpne
427,60 SEK
Høy
431,60 SEK
Lav
426,60 SEK
Markedsverdi
153,21 mrd.
Snittvolum
268,70k
Volum
179,02k
P/E-forhold
114,42
52 u høy
487,00 SEK
52 u lav
293,60 SEK
EPS
3,74 SEK
Utestående aksjer
357,64 mill.
Antall ansatte
2k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Invezz
·
for 2 døgn siden
Dow stiger 423 poeng etter teknologireprise, telekomaksjer faller på SpaceX
Invezz
·
for 3 døgn siden
AI-boblen kan sprekke i 2027 og sende S&P 500 ned til 5 000, advarer strateg
Invezz
·
for 3 døgn siden
Dow åpner 120 poeng lavere etter oljeoppgang og høyere Treasury-avkastning
Chosunbiz
·
for 19 minutter siden
Solidigm opens competitive bid to maximize valuation before Nasdaq push - CHOSUNBIZ
Profil
Sobi - Swedish Orphan Biovitrum AB is an international biopharmaceutical company focused on rare diseases. The company develops, commercializes, and delivers therapies in the fields of haematology, immunology and specialty care. Headquartered in Stockholm, Sweden, with major hubs in Basel, Switzerland, and Waltham, USA.
Sobi has a global presence in approximately 30 countries and provides medicines to patients in many more around world. The company develops treatments for patients living with complex and chronic rare conditions and maintains a pipeline of development and lifecycle management programs focused on advancing innovative therapies for diseases with significant unmet medical needs. Wikipedia
Om Biovitrum